Thoracic Cancer (Feb 2022)

Optimal duration of adjuvant bisphosphonate treatment for high‐risk early breast cancer: Results from a SUCCESS trial

Mingbei Lu,
Beibei Ren,
Lingyan Rao

Affiliations

Mingbei Lu: Department of Thyroid and Breast Surgery Lishui People's Hospital Lishui China
Beibei Ren: Department of Thyroid and Breast Surgery Lishui People's Hospital Lishui China
Lingyan Rao: Department of Thyroid and Breast Surgery Lishui People's Hospital Lishui China

DOI: https://doi.org/10.1111/1759-7714.14257
Journal volume & issue: Vol. 13, no. 3
pp. 519 – 520

Abstract

No abstracts available.

Published in Thoracic Cancer

ISSN: 1759-7706 (Print); 1759-7714 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://onlinelibrary.wiley.com/journal/17597714

About the journal